RT Journal Article
SR Electronic
T1 A preliminary study to evaluate the exposure of human fetus to heavy metals in the umbilical cord blood in Syria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.17.24304428
DO 10.1101/2024.03.17.24304428
A1 Kabbaa, Maryana
A1 Fadel, Ekbal
A1 Mayhoub, Flora
YR 2024
UL http://medrxiv.org/content/early/2024/03/19/2024.03.17.24304428.abstract
AB The environmental situation in Syria needs a comprehensive assessment, especially in light of the conditions it has been experiencing for thirteen years, which have exacerbated pollution with heavy metals (HM) in various regions, including the coastal one.This preliminary and first survey in Syria aims to evaluate the exposure of human fetus in the population to HM by measuring the toxic metals spread in the coastal environment in the umbilical cord blood (UCB), which are lead (Pb), mercury (Hg), cadmium (Cd), arsenic (As), chromium (Cr) and nickel (Ni).The study was conducted between May 2022 and April 2023 among healthy newborns of the National Maternity Hospital in the Mediterranean coastal city of Tartous. This study adopted the official method of the American Association for Analytical Chemistry (AOAC, 2002) in collecting, preserving and processing UCB samples, and the heavy metals were measured using an Atomic Absorption Spectrometer. The statistical study was carried out using SPSS Statistics 23.0 (Statistical Package for Social Sciences).The lower and upper limits for the concentrations of the studied elements in UCB range between: Pb (6.18-17.60µg/L), Hg (1.05-7.62µg/L), Cd (0.01-0.67µg/L), As (0.30-5.70µg/L), Cr (0.02-0.43µg/L), Ni (0.01-0.94µg/L).The concentrations of all HM measured in UCB are below the recommended international reference limits. This paper represents the first step in studying the assessment of fetal exposure to HM in our region. The current and future studies aim to expand the study area to include all of Syria, in addition to linking laboratory levels of HM with various sources of exposure and pregnancy outcomes observed at birth.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial"N/A"Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Research Ethics Committee at Tishreen University - Faculty of MedicineI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.